EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Incorporating diagnostic testing into economic evaluations of tumour-agnostic therapies

Tamás Zelei, Gábor Kovács, Shirin Ashrafganjouei, Tamás Ágh

Expert Review of Pharmacoeconomics & Outcomes Research · 2025

DOI: 10.1080/14737167.2025.2532023 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2025. Verfasst von Tamás Zelei und 3 weiteren Autor:innen. Beteiligte Einrichtung: Syreon Research Institute, Budapest, Hungary. Hauptthemen laut MEDLINE: Neoplasms, Precision Medicine, Molecular Targeted Therapy, Molecular Diagnostic Techniques. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Tumor-agnostic treatments represent paradigm shift in oncology, targeting specific genetic mutations irrespective of the tumor's anatomical origin. This personalized approach relies on companion diagnostic testing to identify patients likely to respond to treatment. However, incorporating molecular diagnostics poses challenges to healthcare systems, particularly regarding costs and accessibility. This must be addressed in economic evaluations to guide health technology assessment and reimbursement decisions. AREAS COVERED: This study reviewed economic evaluations of tumor-agnostic therapies, focusing on the role of diagnostic testing. A literature search identified 13 compounds targeting nine molecular alterations, with eight relevant publications analyzed. The review revealed heterogeneity in how diagnostic testing is incorporated into cost-effectiveness models. While some studies excluded the costs and consequences of diagnostic tests entirely, others included them partially or fully. Key findings underscore the substantial impact of testing, particularly for low-prevalence biomarkers. EXPERT OPINION: Integrating diagnostic testing into economic evaluations is essential for accurately assessing the health economic value of tumor-agnostic therapies. Economic models must account for test-treatment combinations and consider shifts in treatment pathways compared to routine practice. As the field evolves, the development of robust frameworks and clear guidance on the requirements are crucial to support sustainable and equitable healthcare decision-making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsPrecision MedicineMolecular Targeted TherapyMolecular Diagnostic TechniquesHumansCost-Benefit AnalysisTechnology Assessment, BiomedicalModels, EconomicBiomarkers, TumorDecision MakingMutationHealth Services Accessibility

Stichwörter der Autor:innen

Diagnostic testcost-effectivenesseconomic evaluationshealth technology assessment tumour-agnostic therapiesprecision medicine

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Syreon Research Institute, Budapest, Hungary.
  • Semmelweis University, Budapest, Hungary.
  • Center for Health Technology Assessment and Pharmacoeconomic Research, University of Pécs, Pécs, Hungary.

Förderung

  • research

Zitieren

APA

Zelei, T., Kovács, G., Ashrafganjouei, S., & Ágh, T. (2025). Incorporating diagnostic testing into economic evaluations of tumour-agnostic therapies. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2025.2532023

Vancouver

Zelei T, Kovács G, Ashrafganjouei S, Ágh T. Incorporating diagnostic testing into economic evaluations of tumour-agnostic therapies. Expert Review of Pharmacoeconomics & Outcomes Research. 2025. doi:10.1080/14737167.2025.2532023

BibTeX
@article{Zelei2025,
  author = {Zelei, Tamás and Kovács, Gábor and Ashrafganjouei, Shirin and Ágh, Tamás},
  title = {Incorporating diagnostic testing into economic evaluations of tumour-agnostic therapies},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2025},
  doi = {10.1080/14737167.2025.2532023}
}
Kostenlos starten →